Squarepoint
NGM

Squarepoint’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Squarepoint’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-212,916
Closed -$183K – 4766
2023
Q4 		$183K Buy
212,916
+73,257
+52% +$64.3K ﹤0.01% 3630
2023
Q3 		$149K Buy
+139,659
New +$289K ﹤0.01% 3489
2023
Q2 		– Sell
-71,443
Closed -$291K – 4141
2023
Q1 		$291K Sell
71,443
-27,324
-28% -$126K ﹤0.01% 2589
2022
Q4 		$496K Buy
98,767
+72,853
+281% +$457K ﹤0.01% 2294
2022
Q3 		$339K Buy
+25,914
New +$392K ﹤0.01% 2409
2022
Q2 		– Sell
-38,747
Closed -$591K – 3533
2022
Q1 		$591K Buy
38,747
+28,481
+277% +$444K ﹤0.01% 1907
2021
Q4 		$182K Sell
10,266
-5,810
-36% -$111K ﹤0.01% 2747
2021
Q3 		$338K Sell
16,076
-6,220
-28% -$137K ﹤0.01% 2191
2021
Q2 		$440K Sell
22,296
-1,743
-7% -$40.8K ﹤0.01% 2237
2021
Q1 		$699K Buy
24,039
+3,421
+17% +$95.8K ﹤0.01% 1780
2020
Q4 		$625K Buy
+20,618
New +$451K ﹤0.01% 1636
2020
Q3 		– Sell
-29,525
Closed -$583K – 2930
2020
Q2 		$583K Buy
+29,525
New +$564K 0.01% 1231

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Squarepoint's NGM Position: Q1 2024 in Review

Squarepoint sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 212,916 shares — an estimated $183K sold.

Squarepoint first reported a position in NGM in Q2 2020 and held it in 12 quarters. The position peaked at $699K in Q1 2021. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • Squarepoint reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Squarepoint sold 212,916 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $183K.
  • Squarepoint first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
  • Squarepoint's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $699K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Squarepoint's 13F filing for Q1 2024, filed 15 May 2024.